What Does Karyopharm Therapeutics Inc. Do?

Total employees364
HeadquartersNewton
Founded2008

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. The company is dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. and other countries for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Their research focuses on innovative mechanisms to combat cancer and improve patient outcomes.

Where Is Karyopharm Therapeutics Inc.'s Headquarters?

Karyopharm Therapeutics Inc. officeKaryopharm Therapeutics Inc. officeKaryopharm Therapeutics Inc. officeKaryopharm Therapeutics Inc. office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters serves as the central hub for Karyopharm's research and development, clinical operations, commercial strategy, and corporate administration.

Notable Features:

State-of-the-art laboratory facilities for drug discovery and development, combined with modern office spaces designed to promote collaboration and innovation.

Work Culture:

A fast-paced, science-driven environment focused on advancing innovative cancer therapies. Employees often describe a mission-oriented culture with a strong emphasis on teamwork, scientific rigor, and patient impact.

HQ Significance:

Strategically located in the Boston-Cambridge biotech cluster, providing Karyopharm with access to world-class talent, leading research institutions, and numerous industry partners, fostering innovation and collaboration.

Values Reflected in HQ: The headquarters' design and functionality likely reflect Karyopharm's core values of scientific excellence, innovation, urgency in addressing patient needs, and collaboration.

Location:

Karyopharm Therapeutics operates with a global reach, anchored by its U.S. headquarters for research, development, and primary commercial activities. The company is expanding its commercial and clinical presence in key international markets, notably through its European headquarters in Switzerland, and partnerships to bring its novel cancer therapies to patients worldwide. Clinical trials are often conducted across North America, Europe, and Asia-Pacific.

Street Address:

85 Wells Avenue, Suite 210

City:

Newton

State/Province:

Massachusetts

Country:

USA

Where Else Does Karyopharm Therapeutics Inc. Operate Around the World?

Zug, Switzerland

Address: Karyopharm Europe GmbH, Dammstrasse 19, CH-6300 Zug, Switzerland

To facilitate the commercialization and accessibility of Karyopharm's therapies, such as XPOVIO® (selinexor), to patients in Europe and to engage with European regulatory bodies, healthcare professionals, and key opinion leaders.

Buying Intent Signals for Karyopharm Therapeutics Inc.

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Karyopharm Therapeutics Inc.? Meet the Executive Team

As of April 2025, Karyopharm Therapeutics Inc.' leadership includes:

Richard Paulson - President and Chief Executive Officer
Sohanya Cheng, CPA - Chief Financial Officer and Treasurer
Reshma Rangwala, M.D., Ph.D. - Chief Medical Officer
Stuart Poulton - Chief Commercial Officer
Christy J. Oliger - Chief Operating Officer
Jatin Shah, M.D. - Chief Medical Strategy Officer
Ran Frenkel, R.Ph. - Chief Development Operations Officer
Stephen Mitchener, Ph.D. - Chief Business Officer
Patricia Judson - Chief People Officer
Brian G. Kavoogian - General Counsel and Secretary

Who's Investing in Karyopharm Therapeutics Inc.?

Karyopharm Therapeutics Inc. has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock Inc.
State Street Corporation
FMR LLC (Fidelity Management & Research)
Wellington Management Company, LLP

What Leadership Changes Has Karyopharm Therapeutics Inc. Seen Recently?

Hire6
Exits2

Karyopharm Therapeutics has actively refreshed its leadership team over the past 12 months (approx. June 2023 - June 2024), appointing 6 new executives and seeing 2 notable departures, alongside key internal transitions, to strengthen its strategic, operational, and commercial capabilities.

Departures

Michael Mason, Michael Mason resigned from his position as Chief Financial Officer.
Perry A. Steiner, Perry A. Steiner departed from his role as Chief Legal and Compliance Officer.

New Appointments:

Christy J. Oliger, Christy J. Oliger transitioned to Chief Operating Officer.
Sohanya Cheng, CPA, Sohanya Cheng appointed as Chief Financial Officer.
Reshma Rangwala, M.D., Ph.D., Reshma Rangwala appointed as Chief Medical Officer.
Jatin Shah, M.D., Jatin Shah transitioned to Chief Medical Strategy Officer.
Stuart Poulton, Stuart Poulton appointed as Chief Commercial Officer.
Stephen Mitchener, Ph.D., Stephen Mitchener appointed as Chief Business Officer.
Brian G. Kavoogian, Brian G. Kavoogian appointed as General Counsel and Secretary.
Patricia Judson, Patricia Judson appointed as Chief People Officer.

What Technology (Tech Stack) Is Used byKaryopharm Therapeutics Inc.?

Discover the tools Karyopharm Therapeutics Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Karyopharm Therapeutics Inc. Email Formats and Examples

Karyopharm Therapeutics commonly uses the email format combining the first initial and last name. Variations might exist, but this is the most frequently observed pattern.

[first_initial][last]@karyopharm.com

Format

rpaulson@karyopharm.com

Example

85%

Success rate

What's the Latest News About Karyopharm Therapeutics Inc.?

Karyopharm Therapeutics Press Release • June 3, 2024

Karyopharm Therapeutics Presents New Data on Selinexor and Eltanexor at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Karyopharm announced multiple presentations at the 2024 ASCO Annual Meeting, showcasing new clinical and preclinical data for its lead drug selinexor and investigational agent eltanexor across various cancer types, highlighting ongoing research and potential new applications....more

Karyopharm Therapeutics Press Release • May 20, 2024

Karyopharm Therapeutics Announces Positive Topline Results from Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer

The company reported positive topline results from the prespecified interim analysis of the Phase 3 SIENDO study evaluating selinexor as a maintenance therapy in patients with advanced or recurrent endometrial cancer, meeting the primary endpoint of improved progression-free survival....more

Karyopharm Therapeutics Press Release • May 7, 2024

Karyopharm Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm reported its financial results for Q1 2024, detailing XPOVIO® net product revenue, R&D investments, and operational updates. The company also highlighted key clinical advancements and upcoming milestones....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Karyopharm Therapeutics Inc., are just a search away.